1
TÍTULO: Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries  Full Text
AUTORES: Hakan Leblebicioglu; Joop E Arends; Resat Ozaras; Giampaolo Corti; Lurdes Santos; Christoph Boesecke; Andrew Ustianowski; Ann Sofi Duberg; Simona Ruta; Nermin N Salkic; Petr Husa; Ivana Lazarevic; Juan A Pinede; Natalia Yurievna Pshenichnaya; Tengiz Tsertswadze; Mojca Maticic; Edmond Puca; Gulzhan Abuova; Judit Gervain; Ramin Bayramli; Salih Ahmeti; Mairi Koulentaki; Badreddine Kilani; Adriana Vince; Francesco Negro; Mustafa Sunbul; Dominique Salmon; ...Mais
PUBLICAÇÃO: 2018, FONTE: ANTIVIRAL RESEARCH, VOLUME: 150
INDEXADO EM: Scopus WOS
2
TÍTULO: Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I  Full Text
AUTORES: Kosh Agarwal; Emily O Dumas; Giovanni B Gaeta; Sam Lee; Adrian Streinu Cercel; Eckart Schott; Raul J Andrade; Alma M Perez; Jacob George; Igor G Bakulin; Rui T Marinho; Resat Ozaras; Mariem Charafeddine; Li Liu; Tami Pilot Matias; Kevin Howieson; Melannie Co; Daniel E Cohen; Fabien Zoulim;
PUBLICAÇÃO: 2016, FONTE: 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) in HEPATOLOGY, VOLUME: 64
INDEXADO EM: WOS
3
TÍTULO: Time to Viral Suppression is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
AUTORES: Mark S Sulkowski; Michael W Fried; Resat Ozaras; Vasily Isakov; David L Wyles; Peter Ferenci; Jordan J Feld; Filipe Calinas; Michael Gschwantler; Martin King; Tolga Baykal; Edward J Gane;
PUBLICAÇÃO: 2014, FONTE: 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases in HEPATOLOGY, VOLUME: 60
INDEXADO EM: WOS